Cargando…

Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran

PURPOSE: Photoscreening assesses risk factors for amblyopia, as an alternative to measurement of visual acuity (VA) to detect amblyopia, on the premise that its early correction could prevent development of amblyopia. We studied implementations of Plusoptix photoscreening in existing population‐base...

Descripción completa

Detalles Bibliográficos
Autores principales: Bostamzad, Parinaz, Horwood, Anna M., Schalij‐Delfos, Nicoline E., Boelaert, Kristel, de Koning, Harry J., Simonsz, Huibert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003743/
https://www.ncbi.nlm.nih.gov/pubmed/31197950
http://dx.doi.org/10.1111/aos.14144
_version_ 1783494585907937280
author Bostamzad, Parinaz
Horwood, Anna M.
Schalij‐Delfos, Nicoline E.
Boelaert, Kristel
de Koning, Harry J.
Simonsz, Huibert J.
author_facet Bostamzad, Parinaz
Horwood, Anna M.
Schalij‐Delfos, Nicoline E.
Boelaert, Kristel
de Koning, Harry J.
Simonsz, Huibert J.
author_sort Bostamzad, Parinaz
collection PubMed
description PURPOSE: Photoscreening assesses risk factors for amblyopia, as an alternative to measurement of visual acuity (VA) to detect amblyopia, on the premise that its early correction could prevent development of amblyopia. We studied implementations of Plusoptix photoscreening in existing population‐based screening in Flanders and Iran. METHODS: In Flanders, VA is measured at age 3, 4 and 6, photoscreening was added to existing screening at age 1 and 2.5 years in 2013. In Iran, VA is measured at ages 3–6 years, photoscreening was added at ages 3–6 years between 2011 and 2016. Plusoptix use was analysed in the literature for detection of risk factors for amblyopia and amblyopia itself, for ages 0–3 and for 4–6. A questionnaire, containing seven domains: existing vision screening, addition of photoscreening, implementation in screening program, training, attendance, diagnosis and treatment, and costs was distributed. In Iran, screening procedures were observed on site. RESULTS: Implementation of Plusoptix photoscreening was mainly analysed from questionnaires and interviews, its effectiveness from literature data. In Flanders, of 56 759 children photoscreened at age one (81% of children born in 2013), 9.2% had been referred, 13% of these were treated, mostly with glasses, resulting in an increase of 4‐year‐old children wearing glasses from 4.7% to 6.4%. In Iran, 90% of children aged 3–6 years participated in vision screening in 2016, but only those who failed the vision test were subjected to photoscreening. CONCLUSIONS: In Flanders, the use of Plusoptix photoscreening at ages 1 and 2.5 resulted in an increase of children wearing glasses, but it remains unknown how many cases of amblyopia have been prevented. Studies are needed to determine the relation between size and sort of refractive error and strabismus, and the increased chance to develop amblyopia.
format Online
Article
Text
id pubmed-7003743
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70037432020-02-10 Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran Bostamzad, Parinaz Horwood, Anna M. Schalij‐Delfos, Nicoline E. Boelaert, Kristel de Koning, Harry J. Simonsz, Huibert J. Acta Ophthalmol Original Articles PURPOSE: Photoscreening assesses risk factors for amblyopia, as an alternative to measurement of visual acuity (VA) to detect amblyopia, on the premise that its early correction could prevent development of amblyopia. We studied implementations of Plusoptix photoscreening in existing population‐based screening in Flanders and Iran. METHODS: In Flanders, VA is measured at age 3, 4 and 6, photoscreening was added to existing screening at age 1 and 2.5 years in 2013. In Iran, VA is measured at ages 3–6 years, photoscreening was added at ages 3–6 years between 2011 and 2016. Plusoptix use was analysed in the literature for detection of risk factors for amblyopia and amblyopia itself, for ages 0–3 and for 4–6. A questionnaire, containing seven domains: existing vision screening, addition of photoscreening, implementation in screening program, training, attendance, diagnosis and treatment, and costs was distributed. In Iran, screening procedures were observed on site. RESULTS: Implementation of Plusoptix photoscreening was mainly analysed from questionnaires and interviews, its effectiveness from literature data. In Flanders, of 56 759 children photoscreened at age one (81% of children born in 2013), 9.2% had been referred, 13% of these were treated, mostly with glasses, resulting in an increase of 4‐year‐old children wearing glasses from 4.7% to 6.4%. In Iran, 90% of children aged 3–6 years participated in vision screening in 2016, but only those who failed the vision test were subjected to photoscreening. CONCLUSIONS: In Flanders, the use of Plusoptix photoscreening at ages 1 and 2.5 resulted in an increase of children wearing glasses, but it remains unknown how many cases of amblyopia have been prevented. Studies are needed to determine the relation between size and sort of refractive error and strabismus, and the increased chance to develop amblyopia. John Wiley and Sons Inc. 2019-06-14 2020-02 /pmc/articles/PMC7003743/ /pubmed/31197950 http://dx.doi.org/10.1111/aos.14144 Text en © 2019 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Bostamzad, Parinaz
Horwood, Anna M.
Schalij‐Delfos, Nicoline E.
Boelaert, Kristel
de Koning, Harry J.
Simonsz, Huibert J.
Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran
title Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran
title_full Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran
title_fullStr Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran
title_full_unstemmed Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran
title_short Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran
title_sort plusoptix photoscreener use for paediatric vision screening in flanders and iran
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003743/
https://www.ncbi.nlm.nih.gov/pubmed/31197950
http://dx.doi.org/10.1111/aos.14144
work_keys_str_mv AT bostamzadparinaz plusoptixphotoscreeneruseforpaediatricvisionscreeninginflandersandiran
AT horwoodannam plusoptixphotoscreeneruseforpaediatricvisionscreeninginflandersandiran
AT schalijdelfosnicolinee plusoptixphotoscreeneruseforpaediatricvisionscreeninginflandersandiran
AT boelaertkristel plusoptixphotoscreeneruseforpaediatricvisionscreeninginflandersandiran
AT dekoningharryj plusoptixphotoscreeneruseforpaediatricvisionscreeninginflandersandiran
AT simonszhuibertj plusoptixphotoscreeneruseforpaediatricvisionscreeninginflandersandiran